Expertise in
3
conditions

Juan M. Cejalvo

Valencia, VC, ES 
Expertise in
3
conditions
Valencia, VC, ES 

Overview

Juan Cejalvo practices practicing medicine in Valencia, Spain.

Mr. Cejalvo is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Oral Herpes.

He is actively involved in clinical research, co-authoring 76 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Valencia, VC, Spain
Other Locations
Madrid, MD, Spain
Barcelona, CT, Spain
Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II With 2 Parallel Cohorts Clinical Trial Targeting Estrogen Receptor Negative or PAM50 Non-luminal Disease With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer - ATREZZO Study
A Phase II With 2 Parallel Cohorts Clinical Trial Targeting Estrogen Receptor Negative or PAM50 Non-luminal Disease With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer - ATREZZO Study
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drug: Atezolizumab+Trastuzumab+Vinorelbine
Study Phase: Phase 2
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
Enrollment Status: Unknown
Publish Date: June 23, 2023
Intervention Type: Drug
Study Drug: U3 1402
Study Phase: Early Phase 1
View 1 Less Clinical Trial

76 Total Publications

HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.
HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility.
Journal: ESMO open
Published: April 11, 2026

Frequently Asked Questions about Juan M. Cejalvo

Is Juan M. Cejalvo a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Juan M. Cejalvo is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Juan M. Cejalvo participate in research or clinical trials?

Yes. Juan M. Cejalvo has published 76 articles and abstracts on conditions like Breast Cancer. You can view a list of Juan M. Cejalvo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cejalvo's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile